Hainan Huluwa Pharmaceutical Group Co., Ltd. received the Shanghai Stock Exchange\'s “Decision on Termination of the Review of Hainan Huluwa Pharmaceutical Group Co., Ltd.\'s Issuance of Convertible Corporate Bonds to Unspecified Targets”
Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. on the wholly-owned subsidiary obtaining a drug registration certificate for lacosamide oral solution
Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. on issuing convertible corporate bonds to unspecified targets on the results of the review meeting of the Shanghai Stock Exchange Listing Review Committee
Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. about its wholly-owned subsidiary obtaining the registration certificate for ibuprofen suspension drip pharmaceutical.
Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. on the compliance inspection results of pharmaceutical GMP received by its wholly-owned subsidiary.
Legal Opinion of the 2023 Annual General Meeting of Shareholders of Hainan Huluwa Pharmaceutical Group Co., Ltd.
Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders of Hainan Huluwa Pharmaceutical Group Co., Ltd.
Response to the implementation letter of the opinions of the Listing Review Committee Meeting of Hainan Huluwa Pharmaceutical Group Co., Ltd. on the issuance of convertible corporate bonds to unspecified targets
An indicative announcement by Hainan Huluwa Pharmaceutical Group Co., Ltd. on the issuance of convertible corporate bonds to unspecified targets in response to the implementation letter of the Opinions of the Listing Committee Meeting
Ernst & Young Huaming Certified Public Accountants (Special General Partnership) Special Instructions on Hainan Huluwa Pharmaceutical Group Co., Ltd.'s Response to the Implementation Letter of Opinions of the Listing Committee Meeting on Issuance of Convertible Corporate Bonds to Unspecified Targets
Materials of the 2023 Annual General Meeting of Shareholders of Hainan Huluwa Pharmaceutical Group Co., Ltd.
Financial report and audit report of Ernst & Young Huaming Certified Public Accountants (Special General Partnership) on the issuance of convertible corporate bonds by Hainan Huluwa Pharmaceutical Group Co., Ltd. to unspecified targets, and the latest financial report
Beijing Guofeng Law Firm's Supplementary Legal Opinion 4 on Hainan Huluwa Pharmaceutical Group Co., Ltd.'s application to issue convertible corporate bonds to unspecified targets
Letter of sponsorship from CITIC Construction Investment Securities Co., Ltd. regarding the issuance of convertible corporate bonds by Hainan Huluwa Pharmaceutical Group Co., Ltd. to unspecified targets (2023 Financial Data Update)
CITIC Construction Investment Securities Co., Ltd. listing sponsorship letter on the issuance of convertible corporate bonds by Hainan Huluwa Pharmaceutical Group Co., Ltd. to unspecified targets (2023 financial data update)
An indicative announcement by Hainan Huluwa Pharmaceutical Group Co., Ltd. on the update of application documents such as prospectus for issuing convertible corporate bonds to unspecified targets
Ernst & Young Huaming Certified Public Accountants (Special General Partnership) Special Instructions (Revised Draft) on the Response to the Inquiry Letter Reviewing the Application Documents of Hainan Huluwa Pharmaceutical Group Co., Ltd. to Issue Convertible Corporate Bonds to Unspecified Targets (2023 Financial Data Update)
Hainan Huluwa Pharmaceutical Group Co., Ltd. issues convertible corporate bonds prospectus to unspecified targets (previous draft) (2023 financial data update)
Response from Hainan Huluwa Pharmaceutical Group Co., Ltd. and CITIC Construction Investment Securities Co., Ltd. to the review inquiry letter of Hainan Huluwa Pharmaceutical Group Co., Ltd. on the application documents of Hainan Huluwa Pharmaceutical Group Co., Ltd. to issue convertible corporate bonds to unspecified targets (revised draft) (2023 financial data update)
Non-operating capital occupation and other related capital transactions of Hainan Huluwa Pharmaceutical Group Co., Ltd. in 2023
No Data
No Data